IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Trimmed by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,514 shares of the medical research company’s stock after selling 165 shares during the period. Concurrent Investment Advisors LLC’s holdings in IQVIA were worth $1,084,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cumberland Partners Ltd increased its holdings in IQVIA by 6.0% in the fourth quarter. Cumberland Partners Ltd now owns 1,759 shares of the medical research company’s stock valued at $346,000 after buying an additional 99 shares during the last quarter. Ieq Capital LLC increased its holdings in IQVIA by 109.5% in the fourth quarter. Ieq Capital LLC now owns 41,521 shares of the medical research company’s stock valued at $8,159,000 after buying an additional 21,706 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of IQVIA by 1.0% during the fourth quarter. Global Retirement Partners LLC now owns 10,798 shares of the medical research company’s stock valued at $2,122,000 after purchasing an additional 112 shares during the last quarter. Callahan Advisors LLC grew its holdings in shares of IQVIA by 10.9% during the fourth quarter. Callahan Advisors LLC now owns 35,719 shares of the medical research company’s stock valued at $7,019,000 after purchasing an additional 3,506 shares during the last quarter. Finally, Venturi Wealth Management LLC grew its holdings in shares of IQVIA by 710.1% during the fourth quarter. Venturi Wealth Management LLC now owns 1,361 shares of the medical research company’s stock valued at $267,000 after purchasing an additional 1,193 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Activity

In related news, Director John G. Danhakl acquired 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several recent research reports. TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Stifel Nicolaus lowered their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Stock Performance

IQV opened at $190.94 on Friday. The company has a market capitalization of $33.62 billion, a price-to-earnings ratio of 25.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The business has a 50 day moving average price of $199.57 and a two-hundred day moving average price of $216.49.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.